Alitair is a specialty pharmaceutical company focused on developing prescription cough medicines, Orphan Drugs for bronchiectasis as well as leveraging our proprietary ion-exchange resin formulations. Our portfolio of respiratory products and our proprietary formulation technology address unmet medical needs.
Our portfolio consists of patent protected, late-stage, well-characterized small molecules with clear regulatory paths to approval. We will utilize both the FDA 505(b)(2) and Orphan Drug pathways to reduce development costs, shorten approval timelines, and optimize the chances of FDA approval. Our prescription cough and bronchiectasis pipeline products will compete in large established markets that together exceed $5 billion in potential.
Our portfolio consists of patent protected, late-stage, well-characterized small molecules with clear regulatory paths to approval. We will utilize both the FDA 505(b)(2) and Orphan Drug pathways to reduce development costs, shorten approval timelines, and optimize the chances of FDA approval. Our prescription cough and bronchiectasis pipeline products will compete in large established markets that together exceed $5 billion in potential.
Services
Mr. Hoyes began supporting Alitair Pharmaceuticals in late 2016 and was appointed Chief Executive Officer in 2017. He was also appointed to the Board of Directors in 2017. He assumed the Chairman of the Board position in early 2019 upon the retirement of Dr. William Howard. Mr. Hoyes has over 35 years of experience in biopharmaceuticals working on both in industry and in healthcare strategic consulting.
The Alitair Pharmaceutical strategy is to acquire late-stage orphan drug products already approved for therapeutic use outside the United States. This in-licensing-based approach is extremely efficient. In our experience, a typical European-approved product can move rapidly to a late-stage Phase II trial and sometimes a Phase III trial in the United States.
Alitair's patented overdose reduction formulation ODR acts as a passive drug formulation system to reduce the risk of prescription drug overdose no matter how many tablets or capsules are ingested. ODR technology provides appropriate release of a drug at labeled doses but limits drug release at excessive doses.
Alitair Pharmaceuticals focuses on developing innovative treatments using the 505(b)(2) approval pathway for some of its pipeline products. Our patent portfolio includes potential new options and approaches. When coupled with lower research and development costs, these potential indications can be more attractive than traditional, full New Drug Application (NDA) regulatory filings.
Reviews
Be the first to review Alitair Pharmaceuticals.
Write a Review
